Linder the December 19 ct.	F	Approved for use through 10/31/99, OMB 0651 atent and Trademark Office: U.S. DEPARTMENT
Substitute for for factor 1995, no persons are required to respond	to a collection of information	Patent and Trademark Office: U.S. DEPARTMENT OF COMMI
Under the Paperwork Reduction Act of 1995, no persons are required to respond Substitute for form 1449A/PTO	or additional unitess it contains a val	d OMB control number
	Co	mplete if Known
INFORMATION DISCLOSURE		inhiers is known
STATEMENT DISCLUSURE	Application Number	09/506,988
STATEMENT BY APPLICANT		533500,366
O P Rose as manual and		
O Cose as many sheets as necessary)		
/ m	Filing Date	Echanica de
M 2 8 200 C)	First Named Inventor	February 18, 2000 Jordan J.N. Tang
132 4	Group Art Unit	1614
Stept 1 of 6	Examiner Name	1014
MOEMARK	Attorney Docket Number	OMRF 176
OTHER ART. A	ION PATENT LITERAL	
Include name of the author (ION PATENT LITERATURE DOCUMEN in CAPITAL LETTERS), title of the article (who serial, symposium, catalog, etc.), date, page	VTS
item (book, magazine, journal,	in CAPITAL LETTERS), title of the article (wh serial, symposium, catalog, etc.), date, pages ublisher, city and/or country where published	ren appropriate), title of the
BALDWIN, et al., "Structural basis of drug 2(3):244-9 (1995).	ublisher, city and/or country where published	(s), voiume-issue number(s),
2(3):244-9 (1995).	resistance for the V82A mutant of I	HIV-1 proteinase " Not Co-
		Wat. Struct. Biol.
BOGER, Renin Inhibitors. Design of Angio	tensingen Transition	
BOGER, "Renin Inhibitors. Design of Angio restricted inhibitors and a model for the bo Inhibitors, (Kostka, V., ed.), ap. 401-400	ound conformation of rapin substant	Containing Statine:Conformationally
restricted inhibitors and a modal for the bo Inhibitors, (Kostka, V., ed.), pp. 401-420, CARPENTER, et al., "Antiretroviral therepo	Walter de Gruyter:N.Y., 1985	in Aspartic Proteinases and Their
CARPENTER, et al., "Antiretroviral therapy AIDS Society-USA Panel," JAMA 280(1):7	for HIV infection in 1998: Updated	ecommendations of the least
	8-86 (1998).	the international
CARROLL, et al. "Identification of potent in combinatorial library," Bioorg. Med. Chem.	hibitors of Plasmodia Coli	
combinatorial library," Bioorg. Med. Chem.	Lett. 8(17):2315-20 (1998)	asmepsin II from an encoded statine
CARROLL et al "Evaluation (
CARROLL, et al., "Evaluation of a structure plasmepsin II and cathepsin D," Bioorg. Me	-based statine cyclic diamino amide e	encoded combinatorial lib
January Street, Stoory, Me	a. Chem. Lett. 8(22):3203-6 (1998).	combinatorial library against
CHEN, et al "Three dimension		
CHEN, et al., "Three-dimensional structure inhibitors in clinical trials," J. Biol. Chem. 2	70(37):21433-6 (1995)	cross-resistance to all protease
COFFIN. "HIV population		-
COFFIN, "HIV population dynamics in vivo: 267(5197):483-9 (1995).	implications for genetic variation, pat	hogenesis and the
·		solutions, and therapy," Science
CONDRA, et al., "Genetic correlates of in viprotease inhibitor," J. Virol. 70(12):8270-6	VO viral resistant to the	
protease inhibitor," J. Virol. 70(12):8270-6	(1996).	an immunodeficiency virus type 1
CONDRA et al. "/a viii		
CONDRA, et al., "In vivo emergence of HIV- 374(6522):569-71 (1995).	1 variants resistant to multiple protes	se inhihia
	- Protec	Nature
CRAIG, et al., "Antiviral properties of Ro 31- Antiviral Res. 16(4):295-305 (1991).	8950 on inhibit	
Antiviral Res. 16(4):295-305 (1991).	555, all innibitor of human immunor	deficiency virus (HIV) proteinase *
V'		protinger,
Examiners		
Signature MM A	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box →	1	ı

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 stent and Trademark Office: U.S. DEPARTMENT OF COMMERCE	
d OMB control number	

Substitute for form 1449A/PTO		
	C	omplete if Known
INFORMATION DISCLOSURE O PIETEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/506,988
' 0 '	Filling Date First Named Inventor	February 18, 2000 Jordan J.N. Tang
Of 6	Group Art Unit Examiner Name	1614
6 GARAGE OF	Attorney Docket Number	OMRF 176

		OTUES
aminer's	Cite	OTHER ART - NON PATENT LITERATURE DOCUMENTS
nitials*	No.1	
	110.	
		publisher, city and/or country where published published publisher, city and/or country where published
. 1		DEBOUCK & METCALF, "Human Immunodeficiency Virus Protease: A target for AIDS therapy," Drug Devel. Res.
m	- 1	21:1-17 (1990). Drug Devel. Res
' '		
abla		DEBOUCK at all Ellipses
1 1	ł	DEBOUCK, et al., "Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor," Proc. Natl. Acad. Sci. USA 84-8903-8907-4003-4
1 1	ı	specific maturation of the gag precursor," <i>Proc. Natl. Acad. Sci. USA</i> 84:8903-8907 (1987).
+		(1987).
1 1	Į.	DORSEY, et al., "L-735.524; the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a potent and a life in the design of a life in the design
1 1	- 1	DORSEY, et al., "L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor," <i>J. Med. Chem.</i>
1 1	- 1	Siem.
\top		DIAM of all 10 his
1 1	ľ	DUNN, et al., "Subsite preferences of retroviral proteinases," Methods Enzymol. 241:254-178 (1994).
1 /	- }	241.254-178 (1994).
\dashv		
1 1	[8	RMOLIEFF, et al., "Kingtic properties of constitution
1 1	la	RMOLIEFF, et al., "Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protesse and their implications in drug resistance in Vivo." Rinchemistre 26/40) 18884 (1988)
1 1	ľ	protease and their implications in drug resistance in Vivo," Biochemistry 36(40):12364-70 (1997).
		WOOL
lí	1.	noon, et al., "3-tetrahydrofuran and pyran urethanes as high-affinity Pulicaged for UNA
11	p	GHOSH, et al., "3-tetrahydrofuran and pyran urethanes as high-affinity P ₂ -ligands for HIV-1 protease inhibitors," J.
-	1	•
11	G	HOSH, et al., "An efficient synthesis of hydroweth in
- 1 1	lir	HOSH, et al., "An efficient synthesis of hydroxyethylene dipeptide isosteres: The core unit of potent HIV-1 protease hibitors," J. Org. Chem. 56:6500-3 (1991)
- 1-1		o. Org. Chem. 56:6500-3 (1991)
		PAVES ALL
	19	RAVES, "Human immunodeficiency virus proteinase: now, then, what's next?" Adv Exp Med Biol. 306:395-405
1	le.	991). 991).
	_	
1	G	ULNIK, et al., "Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug essure," <i>Biochemistry</i> 34(29):9282-7 (1995).
/ /	DI	essure, Biochemistry 34(29):9282-7 (1995).
1 1	_ r	
 	- 	
	lu.	O, et al., "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," Nature 373(6510):123-6
M	K1	995). 995). 373(6510):123-6

Examiner's	
Signature Mean	Date Considered
Signature Nicht Communication Nicht Comm	1 1 2 1 1 2
	1 / Lea x 2000
*EXAMINER: Initial II reference considered, whether or not citation is in conference considered.	
This is reference considered, whether or not citation is in conference in	

^{*}EXAMINER: Initial I reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Ptease type a plus sign (+) inside this box →	[•]	ĺ
---	-------	---

PTO/S8/08A (10-96 Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OMRF 176

Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 14404/07TO	D a collection of information unless it assesses	OND THE STATE OF COMMERCE		
Substitute for form 1449A/PTO	discrimination in the same and a	valid UMB control number		
		Complete if Known		
INFORMATION DISCLOSURE O STATEMENT BY APPLICANT	Application Number	09/506,988		
(use es many sheets as necessary)	Filing Date			
\ <u>\</u>	First Named Inventor	February 18, 2000		
13 E		Jordan J.N. Tang		
	Group Art Unit	1614		
hoel of Island Mark	Examiner Name			

Attorney Docket Number

xaminer's Initials*	Cite	OTHER ART – NON PATENT LITERATURE DOCUMENTS
	No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
m		DUNN, et al., "Subsite Preferences of Retroviral Proteinases" Methods in Enzymology 241:254-278 (1994).
		HONG, et al., "Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant," <i>Protein Sci.</i> 7(2):300-5 (1998).
		HONG, et al., "Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases," <i>Biochemistry</i> 35:123-126 (1996).
		HOOVER, et al., "Discovery of inhibitors of human renin with high oral bioavailability," Adv Exp Med Biol. 362:167-
		IDO, et al., "Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S," J. Biol. Chem. 266(36):24359-66 (1991).
		JACOBSEN, et al., "Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959," Virology 206(1):527-34 (1995).
	,	JACOBSEN, et al., "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, inetics, and frequencies," <i>J. Infect. Dis.</i> 173(6):1379-87 (1996).
\prod	i.	(EMPF, et al., "ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral sioavailability in humans," <i>Proc. Natl. Acad. Sci. U S A</i> . 92(7):2484-8 (1995).
11	,	OHL, et al., "Active human immunodeficiency virus protease is required for viral infectivity," Proc. Natl. Acad. Sci. //SA 85(13):4686-90 (1988).
K	rı	APATTO, et al., "X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among atroviral enzymes," Nature 342(6247):299-302 (1989).

Examiner's			
	Date Considered (1/2	
Tall the Character Charact	L_ 1/\sqrt{1}	4NT OL	
*EVAMINED. Interview		 	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	T +	ĺ
		ı

PTO/SB/08A (10-96	
Approved for use through 10/31/99. OMB 0651-0031	
tent and Trademark Office: U.S. DEPARTMENT OF COMMERCE	

Substitute for form 1449A/PTO		
	C	omplete if Known
INFORMATION DISCLOSURE	Application Number	09/506,988
PETALEMENT BY APPLICANT		
(use a many sheets as necessary)		
MI 2 8 July 3	Filing Date	February 18, 2000
	First Named Inventor	Jordan J.N. Tang
N AND	Group Art Unit	1614
	Examiner Name	
eel of 6	Attorney Docket Number	OMRF 176

Examiner's	Cite	OTHER ART - NON PATENT LITERATURE DOCUMENTS
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
Me		LIN, et al., "Effect of point mutations on the kinetics and the inhibition of human immunodeficiency type 1 protease: Relationship to drug resistance," <i>Biochemistry</i> 34:1143-1152 (1995).
		MAJER, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," Protein Sci. 6(7):1458-66 (1997).
		MARCINISZYN, et al., "Mode of inhibition of acid proteases by pepstatin," J. Biol. Chem. 251(22):7088-94 (1976).
71		MELLORS, "Closing in on human immunodeficiency virus-1," Nat. Med. 2(3):274-5 (1996).
		MOLLA, et al., "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir," Nat. Med. 2(7):760-6 (1996).
11		MULICHAK & WATENPAUGH, "The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors," <i>J. Biol. Chem.</i> 268(18):13103-9 (1993).
	— 	NAVIA, et al., "Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," Nature 337(6208):615-20 (1989).
	j,	PATICK, et al., "Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human mmunodeficiency virus protease," <i>Antimicrob. Agents Chemother.</i> 40(2):292-7 (1996).
	F ii	PENG, et al., "Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral nfectivity," J. Virol. 63(6):2550-6 (1989).
M	F	POORMAN, et al., "A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base," J. Biol. Chem. 266(22):14554-61 (1991).

Examiner's	
Signature MM La m.	Date Considered A.A
Signature MM de anno	¬ λ/MA
114 111	
V	
AFVALUATED 1 11 AUG.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box \rightarrow	$\overline{}$	
---	---------------	--

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	-	

Under the Paperwork Reduction Act of 1995, no persons are required to recover	al la a sell sur	Patent and Trademark Office: U.S. DEPARTMENT OF CO	OMME
Under the Paperwork Reduction Act of 1995, no persons are required to respon Substitute for form 1449A/PTO	to a collection of information unless it contains a v	alid OMB control number	
	Complete if Known		
INFORMATION DISCLOSURE			
	Application Number	09/506,988	
P ESTATEMENT BY APPLICANT			
P ESTATEMENT BY APPLICANT (as as many sheets as necessary)			
2 8 2000 mg	Filing Date		
1 8 2000 H	First Named Inventor	February 18, 2000	
V 2	Group Art Unit	Jordan J.N. Tang	
SNA L	Examiner Name	1614	
of 6	Attorney Docket Number	OMRF 176	
OTHER ARY			
Examiner's Cite Include name of the author	NON PATENT LITERATURE DOCUM	ENTS	
Initials* No.1 item (book, magazine, journa	(in CAPITAL LETTERS), title of the article (il., serial, symposium, catalog, etc.), date, pag publisher, city and/or country where publisher.	when appropriate), title of the	T 72
	- Li, Jake, par	RISI, VOILIME-ISSUA number/et	Ι΄.
RIDKY & LEIS, "Development of drug res (1995).	sistance to HIV-1 protease inhibitors,	" J. Biol. Chem. 270(50):29621.3	Ь—
			i
RIDKY, et al., "Human immunodeficiency between substrate amino acids bound in	virus, type 1 protease substrate co	naifiain. II II i	
between substrate amino acids bound in	adjacent enzyme subsites," J. Biol.	Chem 271:4709 4717 (1906)	
ROCHEFORT, "Biological and clinical size	16	271.4703.4717 (1996).	
ROCHEFORT, *Biological and clinical sign (1990).	incance of cathepsin D in breast car	ncer," Semin. Cancer Biol. 1(2):153-60	
ROSE, et al., "Human immunodeficiency to protease inhibitors," Proc. Natl. Acad.	virus type 1 viral background plays a	maint role in daysles—	
			
SCHNEIDER & KENT, "Enzymatic activity	of a synthetic 99 residue		
SCHNEIDER & KENT, "Enzymatic activity protease," Cell 54(3):363-8 (1988).	2. 2 synthetic 39 residue protein co	rresponding to the putative HIV-1	
SIMAN et al "Procession of al		1	
SIMAN, et al., "Processing of the beta-am amyloidogenic fragments," J. Biol. Chem.	yloid precursor. Multiple proteases g	enerate and degrade notentially	
	(1000).	í	
SZELKE, "Chemistry of Renin Inhibitors," in (Walter de Gruyter:N.Y., 1985).	n, Aspartic Proteinases and Their lab	Nhitora (Karal	
			\neg
TANG & HARTSUCK, "A kinetic model for			
TANG & HARTSUCK, "A kinetic model for of mutant HIV-1 proteases," FEBS Lett. 36	i7(2):112-6 (1995).	tivity and inhibitor resistance potential	\dashv
		1	
TOH, et al., "Is the AIDS virus recombinant	Nature 316(6023):21-2 (1985).		\dashv
TOMASSELLI, et al. "The complexities of	Alba		
TOMASSELLI, et al., "The complexities of A Chimicaoggi-Chemistry Today 9:6-27 (199	AIDS: An assessment of the HIV pro	tease as a therapeutic target,"	\dashv

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

numan

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.

rease type a plus sign (+) inside this box →	•	PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Inder the Paperwork Reduction Act of 1995, no persons are required to respond to	o a collection of information unless it contains a val	fid OMB control number
Substitute for form 1449A/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/506,988

February 18, 2000

Jordan J.N. Tang

1614

OMRF 176

Filing Date

6

Group Art Unit

Examiner Name

First Named Inventor

Attorney Docket Number

OTHER ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner's Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials* No. publisher, city and/or country where published TONG, et al., "Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced ly amide inhibitor and comparison with HIV-1 protease structures," Proc. Natl. Acad. Sci. USA 90(18):8387-91 (1993). TOWLER, et al., "Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?" Biochemistry 37(49):17137-44 (1998). VACCA, "Design of Tight-Binding Human Immunodeficiency Virus Type 1 Protease Inhibitors," Methods in Enzymology 241:311-334 (1994). WEI, et al., "Viral dynamics in human immunodeficiency virus type 1 infection," Nature 373(6510):117-22 (1995). WEISS, et al., RNA Tumor Viruses, Cold Spring Harbor:NY, 1984. WLODAWER & ERICKSON, "Structure-based inhibitors of HIV-1 protease," Annu. Rev. Biochem. 62:543-85 (1993). WLODAWER, et al., "Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease," Science 245(4918):616-21 (1989).

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's

Signature

Sheel

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.